At PHUSE US Connect 2026 in Austin, PointCross Life Sciences’ Rahul Madhavan, alongside collaborators from Merck Group and Daiichi Sankyo, led a hosted session on “Building a Better MDR” and introduced the soft launch of an industry-first white paper. What began as an observational critique of spreadsheet-based standards management evolved into a broader vision -...
PointCross Life Sciences was proud to participate in PHUSE APAC Connect 2026, held from 19–21 February 2026 in Hyderabad, India. The event brought together global leaders across clinical data science, innovation, and regulatory standards, alongside India CDISC Day, uniting two influential data standards communities under one platform. During the conference, PointCross contributed through both paper and...
Event Date: 16 – 19 November 2025Location: Hamburg, Germany 𝐀𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐚𝐭𝐚 𝐠𝐫𝐨𝐰𝐬 𝐦𝐨𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱, 𝐦𝐞𝐭𝐚𝐝𝐚𝐭𝐚 𝐜𝐚𝐧’𝐭 𝐛𝐞 𝐚𝐧 𝐚𝐟𝐭𝐞𝐫𝐭𝐡𝐨𝐮𝐠𝐡𝐭.At PHUSE EU Connect 2025, Harinarayan Gopichandran, VP Technical Solutions at PointCross, demonstrated how the 𝐗𝐛𝐢𝐨𝐦 𝐒𝐦𝐚𝐫𝐭 𝐌𝐞𝐭𝐚𝐝𝐚𝐭𝐚 𝐑𝐞𝐩𝐨𝐬𝐢𝐭𝐨𝐫𝐲 (𝐌𝐃𝐑) helps Sponsors and CROs 𝘴𝘵𝘳𝘦𝘢𝘮𝘭𝘪𝘯𝘦 clinical trial setup, 𝘢𝘶𝘵𝘰𝘮𝘢𝘵𝘦 metadata governance, and 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 consistency across studies. Managing metadata through...
Validation and study data quality should be thought of as iterative and continuous workflows. Yet, many teams still work within usage models and contract terms that make it harder to validate for rules and conformance checks as often as needed. eDataValidator was designed to change that. Built by PointCross, and used for well over 100,000...
Event Date: Saturday, 22 November 2025Location: Bengaluru, India About the Event The PHUSE Single Day Event (SDE) in Bengaluru brought together leaders across the clinical research ecosystem to discuss how emerging technologies -AI, ML, RPA, and intelligent data systems are transforming clinical data science. With the industry rapidly shifting toward automation and real-time analytics, the event...
Most research organizations spend 16-20 weeks setting up each clinical trial. Six of those weeks go to creating SDTM datasets alone. This isn't just slow. It's expensive, risky, and getting worse as regulatory requirements grow more complex. The problem isn't the work itself. It's how we manage the metadata that gives meaning to clinical data What...
As the BioPharma industry evolves toward more data-intensive, portfolio-wide agile decision-making, under pressure to innovate and reduce the time to market, organizations that master bridging the questions of their staff to regulatory compliant, verifiable responses retrieved from their study data systems will move faster, decide smarter, and ultimately bring therapies to patients more efficiently,...
The biopharmaceutical industry is entering a new era where the ability to harness data directly determines the speed and success of drug development. Clinical trials, nonclinical studies, and biomarker assays now generate massive volumes of complex data. When unified and made accessible, clinical trial data accelerates insights, strengthens regulatory confidence, and reduces development risk. PointCross enables...
The Case for Faster, Smoother Approvals Every day saved in the approval process matters. Faster reviews mean therapies reach patients sooner, investors see value earlier, and science delivers its impact without avoidable setbacks. The encouraging news is that most delays are not because science failed. They happen because submissions were not fully supported by strong data...
Every pharma executive faces the same core challenge: developing safe, efficacious therapies that reach patients while delivering sustainable returns. The industry exists for one fundamental purpose: to discover, develop, and deliver innovative treatments that are both clinically proven and commercially viable. Yet despite record R&D investments, most companies are trapped in cycles that work against...